For the quarter ending 2026-03-31, PTGX made $56,368K in revenue. $3,783K in net income. Net profit margin of 6.71%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| License and collaboration revenue | 56,368 | 7,437 | 4,712 | 5,546 |
| Research and development | 46,739 | 46,358 | 40,003 | 37,036 |
| General and administrative | 13,277 | 11,434 | 11,130 | 10,551 |
| Total operating expenses | 60,016 | 57,792 | 51,133 | 47,587 |
| Loss from operations | -3,648 | -50,355 | -46,421 | -42,041 |
| Interest income | 5,876 | 6,761 | 7,049 | 7,406 |
| Other income, net | 53 | -124 | 33 | 36 |
| Income (loss) before income tax benefit | 2,281 | -43,718 | -39,339 | -34,599 |
| Income tax benefit | -1,502 | 666 | - | 172 |
| Net income (loss) | 3,783 | -44,384 | -39,339 | -34,771 |
| Basic EPS | 0.06 | -0.693 | -0.62 | -0.55 |
| Diluted EPS | 0.05 | -0.693 | -0.62 | -0.55 |
| Basic Average Shares | 65,087,847 | 64,045,517 | 63,772,332 | 63,510,537 |
| Diluted Average Shares | 70,492,618 | 64,045,517 | 63,772,332 | 63,510,537 |
Protagonist Therapeutics, Inc (PTGX)
Protagonist Therapeutics, Inc (PTGX)